Home › Funds › Cormorant Asset Management, LP › ORKA
Cormorant Asset Management, LP position in ORKA
ORUKA THERAPEUTICS INC · Health Care
Cormorant Asset Management, LP reported holding 533,340 shares of ORKA (ORUKA THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$50.8M, representing 2.60% of its reported portfolio and ranking #14 among its reported holdings. Cormorant Asset Management, LP has disclosed ORKA holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Cormorant Asset Management, LP's ORKA position evolved
Cormorant Asset Management, LP first disclosed a stake in ORKA in Q3 2025 at 533,340 shares (US$10.3M). The position peaked in Q2 2026 at 533,340 shares, worth US$50.8M. Across 4 filings, Cormorant Asset Management, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 533,340 shares valued at US$50.8M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 533.34K | $10.26M | New |
| Q4 2025 | 533.34K | $16.17M | Hold |
| Q1 2026 | 533.34K | $26.16M | Hold |
| Q2 2026 | 533.34K | $50.76M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About ORKA and 13F data
ORKA (ORUKA THERAPEUTICS INC) is a Health Care company. 98 other funds we track also report a position in ORKA — the largest reported positions include Venrock Adviser, LLC (US$394.8M), Fairmount Funds Management LLC (US$352.6M), RTW INVESTMENTS, LP (US$298.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ORKA
- Venrock Adviser, LLC 4.15M sh · $394.81M · Q2 2026
- Fairmount Funds Management LLC 3.71M sh · $352.63M · Q2 2026
- RTW INVESTMENTS, LP 3.14M sh · $298.74M · Q2 2026
- Paradigm Biocapital Advisors LP 2.14M sh · $204.09M · Q2 2026
- Deep Track Capital, LP 1.93M sh · $183.30M · Q2 2026
- Bellevue Group AG 1.66M sh · $157.71M · Q2 2026
- Remedium Capital Partners, LLC 1.57M sh · $149.00M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 1.55M sh · $147.95M · Q2 2026
- PERCEPTIVE ADVISORS LLC 1.35M sh · $128.01M · Q2 2026
- Avidity Partners Management LP 760.42K sh · $72.37M · Q2 2026
- SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC 658.30K sh · $62.65M · Q2 2026
- Affinity Asset Advisors, LLC 590.00K sh · $56.15M · Q2 2026
More on Cormorant Asset Management, LP
FAQ
How long has Cormorant Asset Management, LP held ORKA?
Cormorant Asset Management, LP has disclosed ORKA holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Cormorant Asset Management, LP's current position in ORKA?
As of Q2 2026, Cormorant Asset Management, LP holds 533.34K shares of ORKA (ORUKA THERAPEUTICS INC), valued at $50.76M, representing 2.60% of its reported portfolio and ranking #14.
Has Cormorant Asset Management, LP been buying or selling ORKA?
In the latest 13F filing (Q2 2026), Cormorant Asset Management, LP held unchanged its position in ORKA. The position peaked in Q2 2026 at 533.34K shares.
Which other funds hold ORKA?
Other major institutional holders of ORKA include Venrock Adviser, LLC, Fairmount Funds Management LLC, RTW INVESTMENTS, LP, among 98 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.